Kymera Therapeutics (KYMR) Competitors $25.46 +0.03 (+0.12%) Closing price 04:00 PM EasternExtended Trading$25.48 +0.02 (+0.08%) As of 05:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock KYMR vs. LEGN, BPMC, SRPT, TLX, AXSM, KRYS, NUVL, GRFS, ELAN, and VRNAShould you be buying Kymera Therapeutics stock or one of its competitors? The main competitors of Kymera Therapeutics include Legend Biotech (LEGN), Blueprint Medicines (BPMC), Sarepta Therapeutics (SRPT), Telix Pharmaceuticals Limited American Depositary Shares (TLX), Axsome Therapeutics (AXSM), Krystal Biotech (KRYS), Nuvalent (NUVL), Grifols (GRFS), Elanco Animal Health (ELAN), and Verona Pharma (VRNA). These companies are all part of the "pharmaceutical products" industry. Kymera Therapeutics vs. Legend Biotech Blueprint Medicines Sarepta Therapeutics Telix Pharmaceuticals Limited American Depositary Shares Axsome Therapeutics Krystal Biotech Nuvalent Grifols Elanco Animal Health Verona Pharma Kymera Therapeutics (NASDAQ:KYMR) and Legend Biotech (NASDAQ:LEGN) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, earnings, institutional ownership, analyst recommendations, valuation, profitability, community ranking, risk and media sentiment. Which has better earnings & valuation, KYMR or LEGN? Kymera Therapeutics has higher earnings, but lower revenue than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Kymera Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKymera Therapeutics$47.07M35.13-$146.96M-$2.97-8.57Legend Biotech$627.24M9.88-$518.25M-$0.48-70.29 Does the media prefer KYMR or LEGN? In the previous week, Legend Biotech had 4 more articles in the media than Kymera Therapeutics. MarketBeat recorded 14 mentions for Legend Biotech and 10 mentions for Kymera Therapeutics. Legend Biotech's average media sentiment score of 1.16 beat Kymera Therapeutics' score of 1.15 indicating that Legend Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kymera Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Legend Biotech 10 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Do analysts prefer KYMR or LEGN? Kymera Therapeutics currently has a consensus price target of $56.36, indicating a potential upside of 121.36%. Legend Biotech has a consensus price target of $79.00, indicating a potential upside of 134.14%. Given Legend Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Legend Biotech is more favorable than Kymera Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kymera Therapeutics 0 Sell rating(s) 3 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 2.87Legend Biotech 0 Sell rating(s) 1 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.92 Do insiders & institutionals believe in KYMR or LEGN? 70.9% of Legend Biotech shares are held by institutional investors. 15.8% of Kymera Therapeutics shares are held by insiders. Comparatively, 0.0% of Legend Biotech shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Is KYMR or LEGN more profitable? Legend Biotech has a net margin of -66.92% compared to Kymera Therapeutics' net margin of -191.26%. Kymera Therapeutics' return on equity of -24.96% beat Legend Biotech's return on equity.Company Net Margins Return on Equity Return on Assets Kymera Therapeutics-191.26% -24.96% -20.27% Legend Biotech -66.92%-29.69%-19.45% Does the MarketBeat Community believe in KYMR or LEGN? Legend Biotech received 31 more outperform votes than Kymera Therapeutics when rated by MarketBeat users. Likewise, 72.13% of users gave Legend Biotech an outperform vote while only 54.29% of users gave Kymera Therapeutics an outperform vote. CompanyUnderperformOutperformKymera TherapeuticsOutperform Votes5754.29% Underperform Votes4845.71% Legend BiotechOutperform Votes8872.13% Underperform Votes3427.87% Which has more volatility & risk, KYMR or LEGN? Kymera Therapeutics has a beta of 2.22, indicating that its share price is 122% more volatile than the S&P 500. Comparatively, Legend Biotech has a beta of 0.21, indicating that its share price is 79% less volatile than the S&P 500. SummaryLegend Biotech beats Kymera Therapeutics on 11 of the 18 factors compared between the two stocks. Remove Ads Get Kymera Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KYMR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KYMR vs. The Competition Export to ExcelMetricKymera TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.65B$2.90B$5.33B$7.57BDividend YieldN/A1.91%5.11%4.32%P/E Ratio-10.8831.0021.7317.81Price / Sales35.13441.17379.2094.61Price / CashN/A168.6838.1534.64Price / Book3.583.476.464.00Net Income-$146.96M-$72.06M$3.20B$247.23M7 Day Performance20.95%9.33%6.54%7.26%1 Month Performance-25.92%-16.97%-8.55%-6.26%1 Year Performance-25.97%-29.10%10.33%-0.18% Kymera Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KYMRKymera Therapeutics1.4085 of 5 stars$25.46+0.1%$56.36+121.4%-28.5%$1.65B$47.07M-10.88170News CoveragePositive NewsLEGNLegend Biotech2.409 of 5 stars$30.25-5.5%$79.00+161.2%-39.3%$5.56B$627.24M-31.841,070Positive NewsGap UpBPMCBlueprint Medicines2.6248 of 5 stars$80.20-1.8%$124.95+55.8%-5.4%$5.13B$508.82M-74.26640Positive NewsHigh Trading VolumeSRPTSarepta Therapeutics4.6725 of 5 stars$52.40-3.7%$163.18+211.4%-55.5%$5.08B$1.90B41.92840Short Interest ↑High Trading VolumeTLXTelix Pharmaceuticals Limited American Depositary SharesN/A$14.25+4.7%$22.00+54.4%N/A$4.81B$783.21M0.00N/AAXSMAxsome Therapeutics4.5823 of 5 stars$98.50-0.4%$169.80+72.4%+49.7%$4.80B$385.69M-16.44380Analyst RevisionKRYSKrystal Biotech4.6447 of 5 stars$166.01-3.1%$220.00+32.5%-2.7%$4.78B$290.52M55.52210NUVLNuvalent1.9873 of 5 stars$64.68-1.6%$113.44+75.4%+6.9%$4.63BN/A-18.6440Positive NewsGRFSGrifols3.0949 of 5 stars$6.55-1.5%N/A+6.7%$4.50B$7.21B5.6026,300Gap DownELANElanco Animal Health4.3408 of 5 stars$8.95-2.2%$15.17+69.6%-39.4%$4.44B$4.44B22.369,800Analyst ForecastNews CoverageGap DownVRNAVerona Pharma2.2607 of 5 stars$54.30+0.7%$69.14+27.3%+263.4%$4.39B$42.28M-28.2830Positive NewsGap DownHigh Trading Volume Remove Ads Related Companies and Tools Related Companies LEGN Competitors BPMC Competitors SRPT Competitors TLX Competitors AXSM Competitors KRYS Competitors NUVL Competitors GRFS Competitors ELAN Competitors VRNA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KYMR) was last updated on 4/15/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kymera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kymera Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy KYMR Stock Free KYMR Stock Alerts